SailPoint Announces Solution for Migrating Stranded Sun Identity Manager Customers
Offering Helps Companies Avoid Having to “Rip and Replace” Legacy Sun IdM Implementations
SailPoint today announced a migration offering designed to assist organizations faced with the impending end-of-life deadline for Sun Identity Manager (now Oracle Waveset). This comprehensive offering provides organizations with a lower-cost, step-wise path to governance-based identity management, eliminating the need to “rip and replace” their legacy provisioning solution, while providing immediate benefits. The SailPoint migration offering includes: a free assessment tool to help customers gain a clear understanding of their Sun Identity Manager environment and visibility into the areas that need the most attention during migration; a migration tool to help streamline the migration of users, accounts, forms, workflows, and policies from Sun Identity Manager to SailPoint IdentityIQ™; and consultation services that provide implementation expertise and best practices to help ensure a successful migration experience.
“Organizations that have made substantial investments in their Sun Identity Manager implementations are being asked to start over by Oracle, replacing one decade-old technology with another one,” said Trent Fitz, vice president of marketing at SailPoint. “Many customers knew this was coming. But until now, no one has offered a viable upgrade path that allows them to immediately build on their existing Sun investment, and then gradually migrate to a next-generation provisioning solution without disrupting the business. We have already seen an uptick in customers turning to SailPoint to take advantage of our migration path. It was a non-trivial problem to solve, but it helped that the original Sun Identity Manager architects are also the creators of SailPoint IdentityIQ.”
SailPoint IdentityIQ’s user provisioning solution offers out-of-the-box integration with Sun Identity Manager. As a result, SailPoint allows organizations to leverage their existing investment while gradually transitioning to SailPoint IdentityIQ on a timeline that makes sense to IT and the business as a whole. For example, an organization can begin by simply overlaying IdentityIQ on top of Sun Identity Manager to immediately benefit from improved visibility and audit performance through the consolidation of all identity data and controls into a centralized governance framework. Organizations can then migrate their access request and user provisioning processes over time into IdentityIQ to take advantage of its business-friendly user interfaces and automated lifecycle events. Finally, once the organization is ready it can move the underlying connectors from Sun Identity Manager to IdentityIQ without disrupting the business.
SailPoint’s governance-based approach to identity management represents an evolutionary shift in the market and is specifically designed to empower business users to take an active role in governing and managing access. IdentityIQ provides clear, business-friendly descriptions for all access rights, roles, applications, and policies enabling end users to manage their own access and participate in defining and enforcing the policies and processes that govern that access. By involving the business directly in identity management processes, organizations can increase the accuracy of access assignments and reduce their risk of security breaches and failed audits.
Sun Identity Manager customers interested in SailPoint’s migration assessment and tools can visit www.sailpoint.com/sunmigration for more information and to request a consultation with a SailPoint-Sun migration specialist.
About SailPoint
SailPoint, a leader in identity management, helps the world’s largest organizations to mitigate risk, reduce IT costs and ensure compliance. The company’s award-winning software, SailPoint IdentityIQ ™, provides superior visibility into and control over user access to sensitive applications and data while streamlining the access request and delivery process. As the industry’s first business-oriented identity governance suite, IdentityIQ quickly delivers tangible results with risk-aware compliance management, closed-loop user lifecycle management, flexible provisioning, an integrated governance model, and identity intelligence. Visit www.sailpoint.com to learn more.
SailPoint, the SailPoint logo, IdentityIQ, and all techniques are trademarks or registered trademarks of SailPoint Technologies, Inc. in the U.S. and/or other countries. All other products or services are trademarks of their respective companies.
Contact:
SailPoint Technologies, Inc.
Erin Hanley, 512-346-2000 x32
www.sailpoint.com
erin.hanley@sailpoint.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom